CYTK vs. DHR: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CYTK and DHR, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CYTK | DHR |
|---|---|---|
| Company Name | Cytokinetics, Incorporated | Danaher Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 8.21 billion USD | 158.33 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | April 30, 2004 | December 29, 1978 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CYTK and DHR by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CYTK | DHR |
|---|---|---|
| 5-Day Price Return | 6.82% | 4.75% |
| 13-Week Price Return | 71.81% | 4.87% |
| 26-Week Price Return | 117.05% | 12.51% |
| 52-Week Price Return | 18.73% | -8.41% |
| Month-to-Date Return | 4.48% | 2.71% |
| Year-to-Date Return | 41.24% | -3.63% |
| 10-Day Avg. Volume | 1.97M | 3.63M |
| 3-Month Avg. Volume | 2.06M | 4.17M |
| 3-Month Volatility | 91.72% | 31.75% |
| Beta | 0.51 | 0.90 |
Profitability
Return on Equity (TTM)
CYTK
-131.19%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
CYTK has a negative Return on Equity of -131.19%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
DHR
6.88%
Life Sciences Tools & Services Industry
- Max
- 23.81%
- Q3
- 11.79%
- Median
- 7.51%
- Q1
- 3.14%
- Min
- -6.95%
DHR’s Return on Equity of 6.88% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
CYTK
-862.19%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
CYTK has a negative Net Profit Margin of -862.19%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
DHR
14.43%
Life Sciences Tools & Services Industry
- Max
- 33.77%
- Q3
- 17.97%
- Median
- 8.97%
- Q1
- 3.80%
- Min
- -11.89%
DHR’s Net Profit Margin of 14.43% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
CYTK
-795.93%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
CYTK has a negative Operating Profit Margin of -795.93%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
DHR
19.05%
Life Sciences Tools & Services Industry
- Max
- 31.55%
- Q3
- 21.26%
- Median
- 14.06%
- Q1
- 8.54%
- Min
- 0.11%
DHR’s Operating Profit Margin of 19.05% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | CYTK | DHR |
|---|---|---|
| Return on Equity (TTM) | -131.19% | 6.88% |
| Return on Assets (TTM) | -56.45% | 4.40% |
| Net Profit Margin (TTM) | -862.19% | 14.43% |
| Operating Profit Margin (TTM) | -795.93% | 19.05% |
| Gross Profit Margin (TTM) | -- | 59.59% |
Financial Strength
Current Ratio (MRQ)
CYTK
6.88
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
CYTK’s Current Ratio of 6.88 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
DHR
1.52
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.87
- Median
- 1.75
- Q1
- 1.37
- Min
- 0.57
DHR’s Current Ratio of 1.52 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
CYTK
6.01
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 6.01, CYTK operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
DHR
0.33
Life Sciences Tools & Services Industry
- Max
- 0.95
- Q3
- 0.70
- Median
- 0.45
- Q1
- 0.18
- Min
- 0.00
DHR’s Debt-to-Equity Ratio of 0.33 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
CYTK
-16.50
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
CYTK has a negative Interest Coverage Ratio of -16.50. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
DHR
22.31
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
DHR’s Interest Coverage Ratio of 22.31 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | CYTK | DHR |
|---|---|---|
| Current Ratio (MRQ) | 6.88 | 1.52 |
| Quick Ratio (MRQ) | 6.78 | 0.98 |
| Debt-to-Equity Ratio (MRQ) | 6.01 | 0.33 |
| Interest Coverage Ratio (TTM) | -16.50 | 22.31 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
DHR
0.54%
Life Sciences Tools & Services Industry
- Max
- 1.02%
- Q3
- 0.67%
- Median
- 0.32%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Yield of 0.54% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
DHR
24.18%
Life Sciences Tools & Services Industry
- Max
- 97.67%
- Q3
- 61.34%
- Median
- 18.53%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Payout Ratio of 24.18% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | CYTK | DHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.54% |
| Dividend Payout Ratio (TTM) | 0.00% | 24.18% |
Valuation
Price-to-Earnings Ratio (TTM)
CYTK
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for CYTK is currently unavailable.
DHR
44.62
Life Sciences Tools & Services Industry
- Max
- 78.22
- Q3
- 57.42
- Median
- 34.18
- Q1
- 28.39
- Min
- 1.55
DHR’s P/E Ratio of 44.62 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
CYTK
94.74
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
With a P/S Ratio of 94.74, CYTK trades at a valuation that eclipses even the highest in the Biotechnology industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
DHR
6.44
Life Sciences Tools & Services Industry
- Max
- 10.69
- Q3
- 6.37
- Median
- 4.95
- Q1
- 3.27
- Min
- 1.04
DHR’s P/S Ratio of 6.44 is in the upper echelon for the Life Sciences Tools & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
CYTK
58.24
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
At 58.24, CYTK’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
DHR
2.59
Life Sciences Tools & Services Industry
- Max
- 8.12
- Q3
- 5.04
- Median
- 3.94
- Q1
- 2.12
- Min
- 1.13
DHR’s P/B Ratio of 2.59 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | CYTK | DHR |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 44.62 |
| Price-to-Sales Ratio (TTM) | 94.74 | 6.44 |
| Price-to-Book Ratio (MRQ) | 58.24 | 2.59 |
| Price-to-Free Cash Flow Ratio (TTM) | 144.02 | 31.16 |